Mereo BioPharma Group/$MREO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Mereo BioPharma Group

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Ticker

$MREO
Sector
Primary listing

Employees

36

MREO Metrics

BasicAdvanced
$312M
-
-$0.32
0.42
-

What the Analysts think about MREO

Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.

Bulls say / Bears say

Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track with a second interim analysis expected in mid-2025 and a final readout in Q4 2025, demonstrating steady clinical progress.
Mereo held $62.5 million in cash as of March 31, 2025, providing funding runway into 2027 and supporting ongoing development programs.
Alvelestat received Orphan Designation from the European Commission for the treatment of AATD-LD in Q1 2025, reinforcing regulatory exclusivity and attractiveness to potential partners.
Mereo’s shares plunged 33.7% on July 10, 2025, after the Phase 3 Orbit trial did not meet criteria for early termination at the second interim analysis, reflecting investor concern over efficacy thresholds.
The stock has declined 51.14% year-to-date as of early October 2025, underscoring sustained market skepticism toward its pipeline execution.
Total R&D expenses rose to $20.9 million in 2024, up from $17.4 million in 2023, increasing cash burn ahead of potential revenue inflection points.
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

MREO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MREO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MREO

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs